Therefore, CDA1 appears to be an attractive molecular target for treating neoplasia, vascular fibrosis including atherosclerosis, other vascular disorders associated with enhanced TGF-β action, tissue scarring as commonly seen in diabetes. The gene discussed is TSPYL2; the disease is diabetes mellitus.